Cristiana Cipriani1, Sara Piemonte2, Luciano Colangelo3, Viviana De Martino3, Daniele Diacinti4, Federica Ferrone3, Valentina Piazzolla3, Valeria Fassino5, Luciano Nieddu6, Salvatore Minisola3, Jessica Pepe3. 1. Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. cristiana.cipriani@gmail.com. 2. ASL ROMA 1, Distretto 2, via Tagliamento 19, 00198, Rome, Italy. 3. Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. 4. Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. 5. Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. 6. Faculty of Economics, UNINT University, Via Cristoforo Colombo 200, 00147, Rome, Italy.
Abstract
PURPOSE: We evaluated the early effect of denosumab on circulating markers of atherosclerosis in women with postmenopausal osteoporosis. METHODS: Denosumab (60 mg) was administered subcutaneously every 6 months (m) in 27 women (mean age 75 ± 5 years) with postmenopausal osteoporosis and high cardiovascular risk for a total of 24 m. Zoledronic acid was administered in 6 age-matched women as a single intravenous dose. Serum levels of vascular cell adhesion protein 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E and P selectin, CD-40 ligand (CD40L), interleukin-6 (IL-6), matrix metalloproteinase (MMP) 1 and 9, monocyte chemoattractant protein-1 (MCP-1), fibrinogen (FBG), and high sensitivity C-reactive protein (hs-CRP) were measured at baseline, 15 days (d), 2, 6 and 12 m after dosing. In the denosumab group, observation was extended to 24 m as secondary endpoint. RESULTS: Serum ICAM-1 levels showed significant increase in the zoledronic acid group (+18 ± 0.1%; p < 0.01) at 12 m. In the denosumab group, we observed a significant increase in serum CD40L (+2 ± 0.8%; p < 0.001), MMP-1 (+11 ± 0.4%, p < 0.02), and MMP-9 (+39.4 ± 0.8%, p < 0.01) at 24 m. There was a significant increase in serum FBG and hs-CRP in both groups at 12 m (denosumab:+2.2 ± 0.2% and +50.3 ± 1.6%; zoledronic acid: +9.4 ± 0.1 and +81.8 ± 0.8%; p < 0.01). No significant between-group differences were found. CONCLUSIONS: 24-m treatment with denosumab has no effect on the circulating markers of atherosclerosis in women with postmenopausal osteoporosis. Fluctuation of serum ICAM-1, CD40L, MMPs, FBG and hs-CRP can be ascribed to perturbation of immunological mechanisms stimulated by denosumab and zoledronic acid.
PURPOSE: We evaluated the early effect of denosumab on circulating markers of atherosclerosis in women with postmenopausal osteoporosis. METHODS:Denosumab (60 mg) was administered subcutaneously every 6 months (m) in 27 women (mean age 75 ± 5 years) with postmenopausal osteoporosis and high cardiovascular risk for a total of 24 m. Zoledronic acid was administered in 6 age-matched women as a single intravenous dose. Serum levels of vascular cell adhesion protein 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E and P selectin, CD-40 ligand (CD40L), interleukin-6 (IL-6), matrix metalloproteinase (MMP) 1 and 9, monocyte chemoattractant protein-1 (MCP-1), fibrinogen (FBG), and high sensitivity C-reactive protein (hs-CRP) were measured at baseline, 15 days (d), 2, 6 and 12 m after dosing. In the denosumab group, observation was extended to 24 m as secondary endpoint. RESULTS: Serum ICAM-1 levels showed significant increase in the zoledronic acid group (+18 ± 0.1%; p < 0.01) at 12 m. In the denosumab group, we observed a significant increase in serum CD40L (+2 ± 0.8%; p < 0.001), MMP-1 (+11 ± 0.4%, p < 0.02), and MMP-9 (+39.4 ± 0.8%, p < 0.01) at 24 m. There was a significant increase in serum FBG and hs-CRP in both groups at 12 m (denosumab:+2.2 ± 0.2% and +50.3 ± 1.6%; zoledronic acid: +9.4 ± 0.1 and +81.8 ± 0.8%; p < 0.01). No significant between-group differences were found. CONCLUSIONS: 24-m treatment with denosumab has no effect on the circulating markers of atherosclerosis in women with postmenopausal osteoporosis. Fluctuation of serum ICAM-1, CD40L, MMPs, FBG and hs-CRP can be ascribed to perturbation of immunological mechanisms stimulated by denosumab and zoledronic acid.
Authors: Henry G Bone; Rachel B Wagman; Maria L Brandi; Jacques P Brown; Roland Chapurlat; Steven R Cummings; Edward Czerwiński; Astrid Fahrleitner-Pammer; David L Kendler; Kurt Lippuner; Jean-Yves Reginster; Christian Roux; Jorge Malouf; Michelle N Bradley; Nadia S Daizadeh; Andrea Wang; Paula Dakin; Nicola Pannacciulli; David W Dempster; Socrates Papapoulos Journal: Lancet Diabetes Endocrinol Date: 2017-05-22 Impact factor: 32.069
Authors: Allison B Reiss; Nobuyuki Miyawaki; Jane Moon; Lora J Kasselman; Iryna Voloshyna; Robert D'Avino; Joshua De Leon Journal: Atherosclerosis Date: 2018-08-30 Impact factor: 5.162
Authors: E L Simpson; Marrissa Martyn-St James; Jean Hamilton; Ruth Wong; Neil Gittoes; Peter Selby; Sarah Davis Journal: Bone Date: 2019-10-15 Impact factor: 4.398
Authors: A Sardella; F Bellone; N Morabito; S Minisola; G Basile; F Corica; A Catalano Journal: J Endocrinol Invest Date: 2020-09-14 Impact factor: 4.256
Authors: Tobias Puengel; Beate Weber; Theresa H Wirtz; Lukas Buendgens; Sven H Loosen; Lukas Geisler; Burcin Özdirik; Karim Hamesch; Samira Abu Jhaisha; Jonathan F Brozat; Philipp Hohlstein; Albrecht Eisert; Eray Yagmur; Christian Trautwein; Frank Tacke; Alexander Koch Journal: Diagnostics (Basel) Date: 2021-12-28